# Algen Biotechnologies **Source:** https://geo.sig.ai/brands/algen-biotechnologies **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** algenbio.com **Last Updated:** 2026-04-14 ## Summary AI drug discovery platform mapping functional gene networks for novel target identification; $12.63M from Viking Global and YC W20 applying computational genomics to decode disease biology. ## Company Overview Algen Biotechnologies is a San Francisco-based drug discovery company that builds computational platforms to decode functional gene networks — using machine learning and genomic data to map the relationships between genes, understand how gene interactions drive disease, and identify novel therapeutic targets that traditional drug discovery approaches miss because they analyze genes in isolation. Founded in 2018 by Chun Hao Huang and Christine Du and a Y Combinator W20 graduate, Algen raised $12.63 million total including a $9 million Seed VC-II round led by Viking Global Investors in February 2022. Algen's platform addresses a fundamental limitation in genomics-based drug discovery: most genetic analysis identifies individual disease-associated genes, but biology operates through networks — a gene's functional impact depends on which other genes it interacts with, which pathways are co-activated, and the cellular context. Algen's functional genomics platform maps these network relationships from large-scale genetic perturbation data, identifying which gene combinations drive disease phenotypes and which targets are central to therapeutic intervention. In 2025, Algen Biotechnologies competes in the AI drug discovery and computational genomics space with Recursion Pharmaceuticals (RXRX, AI-driven drug discovery), Schrödinger (computational chemistry and biology), Insitro, and academic-spinout gene network platforms for computational drug target identification. The AI drug discovery space has attracted significant investment — Recursion went public, Isomorphic Labs (DeepMind spinout) signed major pharma deals — validating the thesis that computational approaches can accelerate target identification and candidate selection. Viking Global's investment reflects institutional conviction in Algen's gene network approach. The 2025 strategy focuses on advancing lead therapeutic programs from the computational platform into experimental validation, building pharma partnerships for target licensing, and growing the platform's applicability across oncology, neurodegeneration, and metabolic disease. ## Frequently Asked Questions ### What is Algen Biotechnologies? Algen Biotechnologies is a therapeutic discovery company based in San Francisco that builds platforms to decode functional gene networks for drug discovery. Founded in 2018, the company focuses on developing novel drugs by understanding complex gene interactions and biological pathways. ### What products and services does Algen Biotechnologies offer? Algen Biotechnologies offers functional gene network analysis, a drug discovery platform, therapeutic development, gene interaction mapping, and biological pathway analysis. These services focus on understanding complex gene interactions to develop novel therapeutics. ### Who are the target customers of Algen Biotechnologies? Based on their platform and services, Algen Biotechnologies serves pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and therapeutic development. ### When was Algen Biotechnologies founded? Algen Biotechnologies was founded in 2018 by Chun Hao Huang and Christine Du. ### Where is Algen Biotechnologies located? Algen Biotechnologies is based in San Francisco, California. ### How much funding has Algen Biotechnologies raised? Algen Biotechnologies has raised $12.63 million in total funding over 4 rounds. The most recent round was a $9 million Seed VC-II on February 18, 2022, led by Viking Global Investors. ### Who are the investors in Algen Biotechnologies? Algen Biotechnologies is backed by Viking Global Investors, who led their $9M Seed VC-II round, and Y Combinator (W20 batch). ### What technology approach does Algen Biotechnologies use? Algen Biotechnologies uses a platform that decodes functional gene networks to enable drug discovery. Their approach focuses on understanding complex gene interactions and biological pathways to identify novel therapeutic targets. ### Who founded Algen Biotechnologies? Algen Biotechnologies was founded by Chun Hao Huang and Christine Du in 2018. ### What is the latest news about Algen Biotechnologies? The most recent news is that Algen Biotechnologies raised a $9 million Seed VC-II round on February 18, 2022, led by Viking Global Investors. The company is a Y Combinator W20 alum and continues to focus on drug discovery through gene network analysis. ## Tags healthtech, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*